CNS delivery of vectored prion-specific single-chain antibodies delays disease onset

Molecular Therapy : the Journal of the American Society of Gene Therapy
Charles A WuertzerHoward J Federoff

Abstract

A unifying characteristic of prion diseases is the conversion of a normal cellular protein (PrP(c)) to an abnormal pathogenic conformation, designated PrP(sc). Antibodies directed against PrP(c), when added to scrapie-infected cell cultures or passively administered in vivo, can result in elimination of PrP(sc) or prevent its replication, respectively. In our efforts to develop an approach with potential prophylactic utility we employed a recombinant adeno-associated vector type 2 (rAAV2) viral vector platform to express PrP(c)-specific single-chain fragment variable (scFv) antibodies within the central nervous system (CNS) of susceptible mice that were subsequently inoculated peripherally with infectious prions. Vector expressed scFvs delayed onset of prion pathogenesis as evidenced by improvements in clinical signs and rotarod performance, in extended incubation periods, and in decreased PrP(sc) burden in the CNS. This novel antibody delivery platform enables the in vivo translation of prion prophylactics to other species afflicted by transmissible spongiform encephalopathies (TSEs) and which also has relevance to the development of therapeutics for other protein-misfolding diseases such as Alzheimer's or Parkinson's disease.

References

Aug 15, 1992·Proceedings of the National Academy of Sciences of the United States of America·A TaraboulosS B Prusiner
Jul 1, 1968·Journal of Comparative Pathology·A G DickinsonH Fraser
Sep 1, 1996·Journal of Molecular Recognition : JMR·J Malone, M A Sullivan
Apr 11, 2001·Proceedings of the National Academy of Sciences of the United States of America·J M LecerfJ S Huston
Jul 27, 2001·Proceedings of the National Academy of Sciences of the United States of America·M EnariC Weissmann
Nov 1, 2001·Journal of Immunological Methods·C G HaidarisM A Sullivan
Jul 11, 2002·The American Journal of Pathology·Einar M SigurdssonThomas Wisniewski
Jan 31, 2004·Science·Laura SolforosiR Anthony Williamson
Mar 26, 2004·Trends in Microbiology·Markus GlatzelAdriano Aguzzi
Aug 5, 2004·Proceedings of the National Academy of Sciences of the United States of America·Magdalini PolymenidouAdriano Aguzzi
Jun 16, 2005·Journal of Virology·Gaetano DonofrioAdriano Aguzzi
Mar 15, 2006·The Journal of Gene Medicine·S W J McPheeP Leone

❮ Previous
Next ❯

Citations

Oct 22, 2008·Journal of Neuroimmune Pharmacology : the Official Journal of the Society on NeuroImmune Pharmacology·Kathleen A Maguire-Zeiss, Howard J Federoff
May 24, 2013·Neurotherapeutics : the Journal of the American Society for Experimental NeuroTherapeutics·Waldy San SebastianKrystof S Bankiewicz
Jul 30, 2009·Molecular Therapy : the Journal of the American Society of Gene Therapy·Kelly L SudolWilliam J Bowers
Apr 12, 2013·Proceedings of the National Academy of Sciences of the United States of America·Yervand Eduard KarapetyanCorinne Ida Lasmézas
Jul 20, 2010·Immunotherapy·Li LiNeil R Cashman
Sep 21, 2013·International Journal of Molecular Sciences·Liang HuangHoward J Federoff
Jan 8, 2014·Molecular Therapy : the Journal of the American Society of Gene Therapy·Priyanka PatelJean-Pierre Julien
May 8, 2013·Therapeutic Delivery·Marcus W BrazierSteven J Collins
May 28, 2014·Journal of Neuroimmunology·Monique Antoinette DavidMourad Tayebi
Apr 28, 2009·Cellular and Molecular Life Sciences : CMLS·Sabine Gilch, Hermann M Schätzl
Jun 12, 2009·Expert Opinion on Therapeutic Patents·Suehiro SakaguchiHaruo Matsuda
Jul 23, 2009·Expert Review of Anti-infective Therapy·Marcus W BrazierSteven J Collins
Aug 6, 2009·Expert Opinion on Biological Therapy·Anne MesserDavid C Butler
Jan 26, 2011·Expert Opinion on Biological Therapy·Refik PulMartin Stangel
Aug 12, 2008·Trends in Molecular Medicine·Alessio Cardinale, Silvia Biocca
Apr 29, 2009·The Journal of Comparative Neurology·Howard J Federoff
May 18, 2011·Journal of Molecular Recognition : JMR·Anna SladewskaPaulina Czaplewska
Dec 18, 2009·Journal of Molecular Recognition : JMR·Rebecca L Rich, David G Myszka
Apr 9, 2010·The Journal of General Virology·Mourad TayebiMonique David
Sep 13, 2013·International Journal of Cell Biology·Alessio Cardinale, Silvia Biocca
Jul 18, 2015·Current Opinion in Immunology·Cailin E Deal, Alejandro B Balazs
Jan 1, 2012·ISRN Veterinary Science·Peter HedlinScott Napper
Apr 20, 2010·Chembiochem : a European Journal of Chemical Biology·Manuela Bartolini, Vincenza Andrisano
Mar 9, 2019·Journal of Interferon & Cytokine Research : the Official Journal of the International Society for Interferon and Cytokine Research·Denise SkrombolasJohn G Frelinger
Nov 6, 2013·Nature Reviews. Immunology·Adriano AguzziCaihong Zhu
Nov 13, 2008·The Biochemical Journal·Vincenza CampanaChiara Zurzolo
Jul 8, 2020·Expert Opinion on Therapeutic Targets·Arianna Colini BaldeschiGiuseppe Legname
Jun 9, 2017·Journal of Translational Medicine·Kevin Hollevoet, Paul J Declerck
Mar 19, 2020·Pathogens·Yue Ma, Jiyan Ma

❮ Previous
Next ❯

Related Concepts

Related Feeds

Cell-Type-Specific Viral Vectors (ASM)

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

AAV-based Gene Therapy

Adeno-associated virus (AAV)-based gene therapy is a biological vector that is being researched to be used as a potential therapeutic option. This gene therapy is designed to insert fragments of DNA into targeted cells to help treat diseases, such as hemophilia a. Discover the latest research on AAV-based gene therapy here.

Cell-Type Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.

Cell-Type-Specific Viral Vectors

Viral vectors are used in biological research and therapy to deliver genetic material into cells. However, the efficiency of viral vectors varies depending on the cell type. Here is the latest research on cell-type-specific viral vectors.